XLO

Xilio Therapeutics, Inc. [XLO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

XLO Stock Summary

Top 10 Correlated ETFs

XLO

Top 10 Correlated Stocks

XLO

In the News

XLO Financial details

Company Rating
-
Market Cap
40.68M
Income
-75.03M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
73
Optionable
No
Shortable
Yes
Earnings
01 Apr 2024
P/E
-0.31
Forward P/E
-
PEG
0.21
P/S
-
P/B
0.47
P/C
-
P/FCF
-0.33
Quick Ratio
3.53
Current Ratio
3.81
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.73
EPS next Y
-
EPS next Q
-
EPS this Y
-12.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
4.92%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-102%
ROE
-102%
ROC
-1.38%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.49-3.45
52W High
-
52W Low
-
RSI
50
Rel Volume
0.12
Avg Volume
1.21M
Volume
149.14K
Perf Week
-5.07%
Perf Month
-3.09%
Perf Quarter
-41.31%
Perf Half Y
-25.35%
-
-
-
-
Beta
-0.077
-
-
Volatility
0.03%, 0.05%
Prev Close
1.72%
Price
0.7689
Change
-1.31%

Something similar

Top by Market Cap
BRK-B
ABEC.DE
VTI
MSFT
AMZ.DE
Top Correlated ETFs
EWK
ELD
IHY
215620.KS
EFAD
Top Correlated Stocks
ARVN
ITOS
ETON
STOK
CTMX
Similar Market Cap
LEEU.DE
WYLD.ST
NMS
WFH
FAI.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 1.21M
  • Market Capitalization 40.68M
  • Employee 73
  • CEO Dr. Rene Russo BCPS, Pharm.D.
  • Headquarters Waltham,MA,US
  • IPO Date 2021-10-22
  • Website https://www.xiliotx.com

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.